HOPE Therapeutics Treats First Patient with Zeta AI-Guided TMS at Two Clinics
NRXP•HOPE Therapeutics has begun patient treatments using the FDA-cleared Zeta TMS Navigation System at its Sarasota clinic, following installation at both Sarasota and West Palm Beach sites. The system employs proprietary RealTrack AI to register MRI or CT scans to facial anatomy in under two minutes and track coil positioning with sub-millimetric accuracy.
1. First Clinic Deployment
HOPE Therapeutics has installed the FDA-cleared Zeta TMS Navigation System at its clinics in West Palm Beach and Sarasota, with the first patient treatment occurring this week in Sarasota. This marks the initial clinical use of the system within HOPE’s outpatient TMS workflows for treatment-resistant depression patients.
2. RealTrack AI Navigation
The Zeta system uses proprietary RealTrack technology to align a patient’s MRI or CT imaging to their facial anatomy in under two minutes, then continuously monitors the TMS coil’s position relative to the target brain region with sub-millimetric precision. This markerless image guidance leverages artificial intelligence and computer vision for real-time tracking without additional fiducial attachments.
3. Strategic Impact for HOPE Therapeutics
Incorporating surgical-grade navigation into psychiatric care may enhance treatment personalization and consistency, potentially improving outcomes for patients with major depressive disorder and other neuropsychiatric conditions. Successful real-world deployment could position HOPE Therapeutics as a leader in precision-guided TMS services and support broader adoption across its clinic network.
